PROTECT-1 STUDY OF INTESTINE-SPECIFIC CHEMOKINE RECEPTOR ANTAGONIST CCX282-B (TRAFICET-EN) IN CROHN’S DISEASE

(1) On behalf of PROTECT-1 Team, John Radcliffe Hospital, Oxford, United Kingdom

(2) Hepatogastroenterology, Masaryk University, Brno, Czech Republic

(3) Gastroenterol., Rabin Medical Center, Petach Tikva, Israel

(4) Gastroenterol., NZOZ Vivamed, Warszawa, Poland

(5) Int. Med., Praxis für Innere Medizin, Hamburg, Germany

(6) Gastroenterol., Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda., Goiânia, Brazil

(7) Gastroenterol., Petz Aladár Contry and Teaching Hospital, Gyõr, Hungary

(8) Gastroenterol., Royal Adelaide Hospital, Adelaide, Australia

(9) Gastroenterol., Herlev Hospital, Herlev, Denmark

(10) Gastroenterol., UZ Gasthuisberg, Leuven, Belgium

(11) Gastroenterol. & Hepatol., Allgemeines Krankenhaus Wien, Vienna, Austria

(12) Clin. Science & Educ., Karolinska Institutet, Stockholm, Sweden

(13) Int. Med., Christian Albrechts University, Kiel, Germany

(14) Med. & Clin. Affairs

(15) R&D

(16) Medical and Clinical Affairs, ChemoCentryx, Inc., Mountain View, United States



This item was part of the IMMFLAMMATORY BOWEL DISEASE III session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A468